Salvage high-dose-rate interstitial brachytherapy for pelvic recurrent cervical carcinoma after hysterectomy

Naoya Murakami, Tomoyasu Kato, Yuichiro Miyamoto, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Keisuke Tsuchida, Tairo Kashihara, Kazuma Kobayashi, Ken Harada, Mayuka Kitaguchi, Shuhei Sekii, Kana Takahashi, Rei Umezawa, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Jun Itami

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


Background: The aim of this study was to report the clinical results of salvage high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with cervical cancer with pelvic recurrence after hysterectomy. Patients and Methods: When there was no indication for total pelvic extenteration (TPE) and the tumor depth was more than 5 mm of invasion in the paracolpium, salvage HDR-ISBT was applied. Results: A total of 26 patients were included in this study. The median number of fractions and dose per fraction of HDR-ISBT were 5 (range=3-20 fractions) and 6 Gy (range=2.5-6 Gy), respectively. Three-year local control, progression-free survival, and overall survival were 51.1%, 34.4% and 57.1%, respectively. Combination of external-beam radiation therapy, clinical target volume D90 greater than 65 Gy, and dose per fraction greater than 5 Gy were associated with favorable local control. Conclusion: For patients with recurrent cervical cancer post hysterectomy who are not candidates for TPE, salvage HDR-ISBT is a possible curative treatment modality.

Original languageEnglish
Pages (from-to)2413-2421
Number of pages9
JournalAnticancer Research
Issue number5
Publication statusPublished - 2016


  • High-dose-rate interstitial brachytherapy
  • Post hysterectomy relapse
  • Salvage interstitial brachytherapy
  • Uterine cervical cancer


Dive into the research topics of 'Salvage high-dose-rate interstitial brachytherapy for pelvic recurrent cervical carcinoma after hysterectomy'. Together they form a unique fingerprint.

Cite this